Stable high concentration sodium chloride formulations containing PD-1 antibodies and methods of use thereof

By adding specific formulation buffer and surfactant to the antibody subcutaneous formulations to control pH and concentration, the solubility and stability of antibodies at high concentrations are solved, and the injectability and efficacy of subcutaneous injection are improved.

CN119013044APending Publication Date: 2024-11-22BEIGENE GUANGZHOU BIOLOGICS MFG CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380033675.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-14
Filing Date
2023-04-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing antibody subcutaneous formulations have solubility and stability problems at high concentrations, resulting in precipitation or fragmentation, affecting their injectability and efficacy in subcutaneous injection.

Method used

Using drug formulations containing PD-1 antibodies or antigen-binding fragments thereof, buffers, sugar polyols, viscosity reducing agents and nonionic surfactants are prepared, pH is controlled between 5.5-6.0, and trehalose concentration is between 70mM and 160mM. The preparation method of sodium chloride concentration between 50mM and 100mM, polysorbate 20 concentration between 0.02%-0.08%, viscosity does not exceed 30cP, permeability between 200mOsmol/kg and 400mOsmol/kg to ensure the stability and low viscosity of the antibody.

Benefits of technology

The high concentration stability and low viscosity of the antibody are achieved, the injectability and efficacy of subcutaneous injection are enhanced, the shelf life of the formulation is extended, and the difficulties in processing and storage are reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005079256690000121
    Figure BDA0005079256690000121
  • Figure BDA0005079256690000131
    Figure BDA0005079256690000131
  • Figure BDA0005079256690000211
    Figure BDA0005079256690000211
Patent Text Reader

Abstract

The present invention relates generally to the field of pharmaceutical formulations of antibodies or antigen-binding fragments thereof directed against the human programmed death receptor PD-1. These formulations may further contain a histidine buffer, an inorganic salt, a sugar polyol, and a nonionic surfactant. The pharmaceutical formulations of the invention exhibit a low viscosity and a comparable degree of antibody stability upon exposure to heat and other physical stresses. Methods of making such antibody formulations and methods of using such antibody formulations are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Disclosed herein are stable, high-concentration formulations comprising antibodies or antigen-binding fragments thereof that bind to human programmed death receptor 1 (PD-1). Also disclosed herein are methods of preparing these formulations and treating cancer with the formulations of the disclosure. Background Art

[0002] There has been an increase in the use of antibodies as therapeutic agents in the clinic. However, while antibodies generally have similar structures, they differ in primary amino acid sequence, even for antibodies that bind to the same target protein. The characteristics of the primary amino acid sequence of an antibody are one of the main determinants of the solubility and / or stability properties of the antibody in different formulations. An antibody formulation that provides solubility and stability for one antibody may perform poorly for another, resulting in antibody precipitation or fragmentation. This is particularly true when a subcutaneous antibody formulation is desired.

[0003] Subcutaneous injection has received increasing attention in the delivery of protein therapeutics because it provides patients with the potential for self-administration. Through rapid, low-volume injections, patients can administer antibody therapeutics without the need for intravenous infusions, which typically require a visit to the hospital. However, many antibodies require a certain dose to be effective, and the antibodies usually need to be concentrated into a small volume. The volume limitation of the subcutaneous administration route is a key factor to be considered for subcutaneous administration, resulting in the need for high-concentration antibody doses. In turn, this has created challenges related to the solubility of proteins, physical and chemical stability, and the manufacture, storage and delivery difficulties of subcutaneous antibody formulations. For example, antibodies lose solubility during processing and / or storage and form particles in certain formulations, which makes subcutaneous administration less effective. Due to the concentrated nature of antibodies in subcutaneous formulations, high viscosity is another problem to be overcome because it limits the injectability of the product. In addition, during the manufacturing process, high-viscosity antibody formulations have difficulties in processing, especially in ultrafiltration and sterile filtration. Finally, subcutaneous antibody formulations need to maintain the structure and function of antibodies. Subcutaneous antibody formulations that result in proteolysis or structural degradation of the antibody will reduce efficacy, as well as impair the ability of the antibody to bind to its target protein.

[0004] Therefore, there has long been a need in the art for subcutaneous antibody formulations of anti-human PD-1 antibodies for the treatment of various cancers and infectious diseases. Such formulations can have good antibody solubility, stability, long shelf life, and are easy to administer at high concentrations. Summary of the invention

[0005] The present disclosure provides a stable, low-viscosity and high-concentration antibody formulation. A low-viscosity pharmaceutical formulation comprising: about 10 mg / mL to about 200 mg / mL of an anti-programmed death receptor 1 (PD-1) antibody, or an antigen-binding fragment thereof; a formulation buffer providing a pH of about 5.0 to about 7.0; Sugar polyols; Viscosity reducers; and Nonionic surfactants, The viscosity of the pharmaceutical formulation does not exceed 30 cP, and the osmolarity is from about 200 mOsmol / kg to about 400 mOsmol / kg.

[0006] The formulation, wherein the PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (a) HCDR1 (heavy chain complementary determining region 1) of SEQ ID NO: 1, (b) HCDR2 of SEQ ID NO: 2, (c) HCDR3 of SEQ ID NO: 3, and the light chain variable region comprising: (d) LCDR1 (light chain complementary determining region 1) of SEQ ID NO: 4, (e) LCDR2 of SEQ ID NO: 5, and (f) LCDR3 of SEQ ID NO: 6.

[0007] The formulation, wherein the formulation buffer is selected from the group consisting of: histidine, acetate, citrate, succinate, phosphate, a mixture of histidine and acetic acid, or a mixture of histidine and citric acid.

[0008] The formulation, wherein the formulation buffer is histidine.

[0009] The formulation, wherein the concentration of the buffer is 15 mM to 25 mM.

[0010] The formulation, wherein the formulation comprises 20 mM histidine buffer.

[0011] The formulation, wherein the pH is 5.5-6.0.

[0012] The formulation, wherein the sugar polyol is selected from the group consisting of trehalose, sucrose, sorbitol, mannitol, maltose, dextran, or (2-hydroxypropyl)-β-cyclodextrin.

[0013] The formulation, wherein the sugar polyol is trehalose.

[0014] The formulation, wherein the trehalose concentration is 70 mM to 240 mM.

[0015] The formulation, wherein the trehalose concentration is 80 mM to 160 mM.

[0016] The formulation, wherein the trehalose concentration is 70 mM to 100 mM.

[0017] The formulation, wherein the trehalose concentration is 80 mM.

[0018] The formulation, wherein the viscosity reducing agent is an inorganic salt selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium sulfate, ammonium chloride or ammonium sulfate.

[0019] the formulation, wherein the inorganic salt is sodium chloride at a concentration of 50 mM to 150 mM,

[0020] The formulation, wherein the concentration of sodium chloride is 50 mM to 100 mM.

[0021] The formulation, wherein the sodium chloride concentration is 70 mM.

[0022] The formulation, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 or poloxamer 188.

[0023] The formulation, wherein the concentration of polysorbate 20 is 0.02% to 0.08%.

[0024] The preparation, wherein the concentration of polysorbate 20 is 0.08%.

[0025] The formulation, wherein the formulation comprises 20 mM histidine-histidine HCl, 100 mM NaCl, 70 mM trehalose and 0.08% polysorbate 20, has a pH of pH 6.0.

[0026] The formulation, wherein the formulation comprises 20 mM histidine-histidine HCl, 50 mM NaCl, 100 mM trehalose and 0.02% polysorbate 20, has a pH of pH 6.0.

[0027] The formulation, wherein the formulation comprises 20 mM histidine-histidine HCl, 70 mM NaCl, 80 mM trehalose and 0.08% polysorbate 20, has a pH of pH 6.0.

[0028] The formulation, wherein the concentration of the anti-human PD-1 antibody, or antigen-binding fragment thereof, is about 10 mg / mL to 200 mg / mL.

[0029] A method for preparing an antibody formulation, the method comprising: a. adding trehalose and sodium chloride to the antibody to obtain an antibody formulation in which the concentration of trehalose is not less than 50 mM and the concentration of sodium chloride is not less than 25 mM, wherein the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (a) HCDR1 (heavy chain complementary determining region 1) of SEQ ID NO: 1, (b) HCDR2 of SEQ ID NO: 2, (c) HCDR3 of SEQ ID NO: 3, and the light chain variable region comprising: (d) LCDR1 (light chain complementary determining region 1) of SEQ ID NO: 4, (e) LCDR2 of SEQ ID NO: 5, and (f) LCDR3 of SEQ ID NO: 6; b. concentrating the antibody preparation of (a) to 150-200 mg / mL; and c. adding polysorbate 20 to the antibody formulation of (b) to obtain an antibody formulation having a polysorbate 20 concentration of not less than 0.01 mg / mL, wherein the antibody formulation of (c) is in aqueous solution and has a viscosity of no more than 30 cP at 25°C, and wherein the antibody formulation of (c) is stable after agitation, freeze-thaw and thermal stress.

[0030] A method for treating cancer in a human patient in need thereof, the method comprising subcutaneously administering an effective amount of an anti-human PD-1 antibody formulation.

[0031] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of about 100 mg to about 1000 mg.

[0032] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 200 mg.

[0033] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 300 mg.

[0034] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 400 mg.

[0035] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 500 mg.

[0036] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once a week.

[0037] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once every 2 weeks.

[0038] The method, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once every 3 weeks.

[0039] The method, wherein the cancer is lung cancer (including small cell lung cancer, or non-small cell lung cancer), adrenal cancer, liver cancer, stomach cancer, cervical cancer, melanoma, kidney cancer, breast cancer, colorectal cancer, leukemia, bladder cancer, bone cancer, brain cancer, endometrial cancer, head and neck cancer, lymphoma, ovarian cancer, skin cancer, thyroid tumor, or esophageal cancer.

[0040] The method, wherein at least one other therapeutic agent is administered to the human patient, the other therapeutic agent being zanubrutinib, pamiparib, anti-CTLA4 antibody, anti-4-1BB antibody, anti-OX40 antibody, anti-TIGIT antibody, anti-TIM-3 antibody, CD40 agonist, TLR agonist, CAR-T cell, or chemotherapeutic agent.

[0041] In some embodiments, the antibody formulation comprises an anti-PD-1 antibody, or an antigen-binding fragment thereof, a formulation buffer, a sugar polyol, a viscosity reducer, and a nonionic surfactant. In some embodiments, the formulation buffer provides a pH range between 5.0 and 7.0. In some embodiments, the viscosity of the antibody formulation does not exceed 30 centipoise (cP). In some embodiments, the osmotic pressure of the antibody formulation is about 200mOsmol / kg to about 400mOsmol / kg. In some embodiments, the antibody formulation is stable after stirring, freeze-thaw and thermal stress.

[0042] In some embodiments, the antibody formulation may include an anti-PD-1 antibody or antigen-binding fragment thereof at between about 10 mg / mL and about 200 mg / mL, a formulation buffer, a sugar polyol, a viscosity reducer, and a nonionic surfactant, and the pH is about 6.0±0.5. In some embodiments, the antibody formulation may consist essentially of: about 100 mg / mL to about 180 mg / mL of an anti-PD-1 antibody, a formulation buffer, a sugar polyol, a viscosity reducer, and a nonionic surfactant, and the pH is about 6.0±0.5.

[0043] In some embodiments, the formulation buffer is selected from the group consisting of: histidine, acetate, citrate, succinate, phosphate, a mixture of histidine and acetic acid, a mixture of histidine and citric acid. In some embodiments, the formulation buffer can be a histidine buffer. In some embodiments, the concentration of the histidine buffer is about 10mM to about 30mM. In some embodiments, the concentration of the histidine buffer is about 20mM histidine.

[0044] In some embodiments, the sugar polyol is selected from the group consisting of trehalose, sucrose, sorbitol, mannitol, maltose, dextran, or (2-hydroxypropyl)-β-cyclodextrin. In some embodiments, the sugar polyol can be trehalose. In some embodiments, trehalose is α, α-trehalose dihydrate. In other embodiments, the sugar polyol can be sucrose. In some embodiments, the concentration of the sugar polyol can be about 25mM to about 240mM. In some embodiments, the concentration of the sugar polyol can be about 50mM to about 150mM, preferably about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, or about 100mM.

[0045] In certain embodiments, the viscosity reducing agent is an inorganic salt. In certain embodiments, the viscosity reducing agent is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium sulfate, ammonium chloride or ammonium sulfate. In certain embodiments, the viscosity reducing agent is sodium chloride. In certain embodiments, the concentration of sodium chloride can be about 25mM to about 150mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM or about 100mM.

[0046] In some embodiments, the nonionic surfactant is selected from the group consisting of polysorbate 80 (PS80), polysorbate 20 (PS20) or poloxamer 188. In some embodiments, the concentration of the nonionic surfactant can be about 0.01 to about 1 mg / mL. In some embodiments, the concentration of polysorbate is about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, or about 0.8 mg / mL. In some embodiments, the polysorbate is polysorbate 20.

[0047] In some embodiments, the antibody formulation comprises about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 135 mg / mL, about 140 mg / mL, about 145 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL. In some embodiments, the present invention provides an antibody formulation of about 100 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL or about 200 mg / mL of an anti-PD-1 antibody, or an antigen-binding fragment thereof, about 20 mM histidine buffer, about 70 mM to about 100 mM α, α-trehalose dihydrate or sucrose, about 50 mM to about 100 mM sodium chloride, about 0.2 mg / mL to about 0.8 mg / mL polysorbate 20, and the pH of the antibody formulation is 6.0 ± 0.5. In some embodiments, the viscosity of the antibody formulation is no more than 30 cP at 25 ° C.

[0048] In some embodiments of the present invention, the anti-PD-1 antibody is tislelizumab (BGB-A317) or an antigen-binding fragment of tislelizumab.

[0049] Also provided herein is a method for preparing a stable, low-viscosity antibody formulation, the method comprising: adding trehalose or sucrose and sodium chloride to the antibody to obtain an antibody formulation having a trehalose or sucrose concentration of not less than 50 mM and a sodium chloride concentration of not less than 25 mM, concentrating the antibody to about 200 mg / mL; adding polysorbate 20 to the antibody formulation to obtain an antibody formulation comprising polysorbate 20 at a concentration of not less than 0.01 mg / mL, wherein the antibody formulation is an aqueous solution and has a viscosity of no more than 30 cP at 25°C.

[0050] Also provided herein is a method of treating cancer in a human patient having cancer, the method comprising subcutaneously administering to the patient an effective amount of a PD-1 antibody formulation as described herein.

[0051] Provided herein are methods of treating cancer in a human patient having a cancer that expresses PDL-1, the method comprising subcutaneously administering to the patient an effective amount of a PD-1 antibody formulation as described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 shows the results of SEC-HPLC studies (Figure 1A) and CZE studies (Figure 1B) of 10 mg / ml tislelizumab formulations stored at 40°C for 2 weeks (denoted as "40C2W" in the figure) and exposed to light for 2 weeks (denoted as "pho2W" in the figure). T0 refers to the initial point of the sample.

[0053] Figure 2A-B The amount of aggregates (FIG. 2A) and monomers (FIG. 2B) of each formulation after freeze-thaw (denoted as "3FT" in the figure), shaking (denoted as "SK" in the figure), and thermal stress (denoted as "40C4W" in the figure) as measured by SEC-HPLC is shown. T0 refers to the initial point of the sample. "25C6M" indicates that the formulation was stored at 25°C for 6 months. "5C6M" indicates that the formulation was stored at 5°C for 6 months.

[0054] Figure 3 Results of CZE studies of subcutaneous antibody formulations stored at 40°C for a period of 4 weeks (denoted as "40C4W" in the figure) are shown. T0 refers to the initial time point. "25C6M" indicates that the formulation was stored at 25°C for 6 months. "5C6M" indicates that the formulation was stored at 5°C for 6 months.

[0055] Figure 4 The purity of the formulation at 40°C over a 4 week period (denoted as "40C4W" in the figure) as measured by CE-SDS under non-reducing conditions is shown. T0 refers to the initial time point. "25C6M" indicates that the formulation was stored at 25°C for 6 months. "5C6M" indicates that the formulation was stored at 5°C for 6 months.

[0056] Figure 5 shows the results of SEC-HPLC studies (Figures 5A and 5B), CZE studies (Figure 5C) and CE-SDS (NR) studies (Figure 5D) of formulation F18 stored at 25°C (denoted as "25C") and 5°C ± 3°C (denoted as "5C"). "0" month refers to the initial time point of the sample.

[0057] Fig. 6A -B shows data on the bioavailability of F18 subcutaneous formulation in the Sprague Dawley rat model.

[0058] Figure 7 Bioavailability data of F18 subcutaneous formulation in monkey model are shown.

[0059] Figure 8 are photographs showing that both rats and minipigs had no injection site reactions when subcutaneous formulations were administered at different sites in the animals. DETAILED DESCRIPTION definition

[0060] Unless explicitly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art.

[0061] As used herein, including the appended claims, singular forms such as "a," "an," and "the" include their corresponding plural referents unless the context clearly dictates otherwise.

[0062] Unless the context clearly indicates otherwise, the term "or" is used to mean and is interchangeable with the term "and / or."

[0063] Throughout this specification and the following claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" will be understood to implicitly include the stated amino acid sequence, DNA sequence, steps or groups thereof, but not to exclude any other amino acid sequence, DNA sequence, step. When used herein, the term "comprising" may be replaced with the terms "containing", "including", or sometimes "having".

[0064] The terms "administration / administering" and "treating / treatment" herein, when applied to animals, humans, experimental subjects, cells, tissues, organs or biological fluids, mean that an exogenous drug, therapeutic agent, diagnostic agent, or antibody formulation is in contact with the animal, human, subject, cell, tissue, organ, or biological fluid. The treatment of cells encompasses the contact of reagents with cells and the contact of reagents with fluids, wherein the fluid is in contact with cells. The terms "administration" and "treatment" also refer to in vitro and ex vivo treatments, for example, cells are treated by reagents, diagnostic agents, binding compounds or by another cell. The term "subject" herein includes any organism, preferably an animal, more preferably a mammal (e.g., rats, mice, dogs, cats, rabbits), and most preferably a human. On the one hand, treating any disease or disorder refers to improving the disease or disorder (i.e., slowing down or preventing or reducing the development of a disease or at least one clinical symptom thereof). On the other hand, "treat, treating or treatment" refers to alleviating or improving at least one physical parameter, including those that the patient may not be able to discern. In yet another aspect, "treat," "treating," or "treatment" refers to modulating the disease or disorder physically (eg, stabilization of a discernible symptom), physiologically (eg, stabilization of a physical parameter), or both.

[0065] As used herein, the term "therapeutically effective amount" refers to an amount of an anti-PD-1 antibody sufficient to affect the treatment of a disease, disorder, or symptom when administered to a subject to treat a disease, or at least one clinical symptom of a disease or disorder. The "therapeutically effective amount" may vary with the agent, the disease, disorder, and / or symptoms of the disease or disorder, the severity of the disease, disorder, and / or symptoms of the disease or disorder, the age of the subject to be treated, and / or the weight of the subject to be treated. The appropriate amount in any given case will be apparent to one skilled in the art or may be determined by routine experimentation. In the case of combination therapy, a "therapeutically effective amount" refers to the total amount of the combination subject used to effectively treat a disease, disorder, or condition. In some embodiments of the present disclosure, the subject is a human.

[0066] "Pharmaceutical formulation" or "formulation" refers to a preparation of an antibody that is in a form that permits the active ingredients to be effective and that contains no additional components that are toxic to a subject to which the formulation is administered.

[0067] A "stable" formulation is a formulation of an antibody that is prepared in such a way that the physical stability and / or chemical stability and / or biological activity of the antibody is maintained over time. Various analytical techniques for measuring protein stability are available in the art and are reviewed in the following literature: Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York City, New York, published in (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature over a selected time period.

[0068] The term "antibody" is used in the broadest sense herein and specifically encompasses antibodies (including full-length monoclonal antibodies) and antibody fragments, as long as they recognize an antigen, such as PD-1. Antibodies are typically monospecific, but may also be described as heterospecific, heterospecific, or multispecific. Antibody molecules bind to specific antigenic determinants or epitopes on an antigen through specific binding sites.

[0069] The term "monoclonal antibody" or "mAb" or "Mab" herein refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules contained in the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in small amounts. In contrast, conventional (polyclonal) antibody preparations typically include a variety of different antibodies with different amino acid sequences in their variable domains, particularly their complementary determining regions (CDRs), which are typically specific for different epitopes. The modifier "monoclonal" indicates the characteristics of antibodies obtained from a substantially homogeneous antibody population and should not be construed as requiring antibodies to be produced by any particular method. Monoclonal antibodies (mAbs) can be obtained by methods known to those skilled in the art. See, e.g., Kohler G et al., Nature 1975 256:495-497; U.S. Pat. No. 4,376,110; Ausubel FM et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 1992; Harlow E et al., ANTIBODIES: A LABORATORY MANUAL, Cold spring Harbor Laboratory 1988; and Colligan JE et al., CURRENT PROTOCOLS IN IMMUNOLOGY 1993. The mAbs disclosed herein can be of any immunoglobulin class, including IgG, IgM, IgD, IgE, IgA, and any subclass thereof. The hybridoma producing the mAb can be cultured in vitro or in vivo. High titer mAbs can be obtained by in vivo production, in which cells from a single hybridoma are injected intraperitoneally into mice, such as primary primed Balb / c mice, to produce ascites fluid containing high concentrations of the desired mAb. MAbs of isotype IgM or IgG can be purified from such ascites fluid, or from culture supernatants, using column chromatography methods well known to those skilled in the art.

[0070] Typically, the basic antibody structural unit comprises a tetramer. Each tetramer includes two pairs of identical polypeptide chains, each pair having a "light chain" (about 25 kDa) and a "heavy chain" (about 50-70 kDa). The amino terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The carboxyl terminal portion of the heavy chain can be defined as a constant region that is primarily responsible for effector function. Typically, human light chains are classified as κ and λ light chains. In addition, human heavy chains are typically classified as α, δ, ε, γ or μ, and the isotype of the antibody is defined as IgA, IgD, IgE, IgG and IgM, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 10 or more amino acids.

[0071] The variable regions of each light chain / heavy chain (VL / VH) pair form an antibody binding site. Therefore, in general, a complete antibody has two binding sites. Except for bifunctional or bispecific antibodies, in general, the two binding sites are identical.

[0072] Typically, the variable domains of both the heavy and light chains contain three hypervariable regions, also referred to as "complementarity determining regions (CDRs)", which are located between relatively conserved framework regions (FRs). The CDRs are usually aligned by the framework regions to enable binding to specific epitopes. In general, from N-terminus to C-terminus, both the light and heavy chain variable domains contain FR-1 (or FR1), CDR-1 (or CDR1), FR-2 (FR2), CDR-2 (CDR2), FR-3 (or FR3), CDR-3 (CDR3), and FR-4 (or FR4) in order. In general, the amino acid assignments for each domain conform to the definition of an immunologically interesting protein sequence, Kabat et al., National Institutes of Health, Bethesda, Maryland; 5th ed.; NIH Publication No. 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32: 1-75; Kabat et al., (1977) J. Biol. Chem. 252: 6609-6616; Chothia et al., (1987) J Mol. Biol. 196: 901-917 or Chothia et al., (1989) Nature 342: 878-883.

[0073] The term "hypervariable region" refers to the amino acid residues in an antibody that are responsible for antigen binding. The hypervariable region comprises amino acid residues from the "CDRs" (i.e., VL-CDR1, VL-CDR2, and VL-CDR3 in the light chain variable domain and VH-CDR1, VH-CDR2, and VH-CDR3 in the heavy chain variable domain). See Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Maryland (defining the CDR regions of antibodies by sequence); see also Chothia and Lesk (1987) J. Mol. Biol. 196:901-917 (defining the CDR regions of antibodies by structure). The term "framework" or "FR" residues is intended to refer to those variable domain residues other than the hypervariable region residues herein defined as CDR residues.

[0074] Unless otherwise indicated, "antibody fragment" or "antigen-binding fragment" refers to an antigen-binding fragment of an antibody, i.e., an antibody fragment that retains the ability to specifically bind to an antigen bound by a full-length antibody, such as a fragment that retains one or more CDR regions. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules (e.g., single-chain Fv (ScFv)); nanobodies, and multispecific antibodies formed from antibody fragments.

[0075] Antibodies that specifically bind to a particular target protein are also described as specifically binding to a particular target protein. This means that compared to other proteins, the antibody shows preferential binding to the target protein, but this specificity does not require absolute binding specificity. If the binding of the antibody determines the presence of the target protein in the sample, for example, no undesirable results, such as false positives, are produced, the antibody is considered to be "specific" for its intended target. Antibodies or binding fragments thereof that can be used in the present invention will bind to the target protein with an affinity that is at least twice higher than that of the non-target protein, preferably at least 10 times higher, more preferably at least 20 times higher, and most preferably at least 100 times higher. The antibodies herein are referred to as specifically binding to a polypeptide comprising a given amino acid sequence.

[0076] The term "human antibody" as used herein means an antibody that comprises only human immunoglobulin protein sequences. If produced in mice, mouse cells, or hybridomas derived from mouse cells, human antibodies may contain murine carbohydrate chains. Similarly, "mouse antibody" or "rat antibody" means an antibody that comprises only mouse or rat immunoglobulin protein sequences, respectively.

[0077] The term "humanized antibody" means an antibody form containing sequences from non-human (e.g., mouse) antibodies and human antibodies. Such antibodies contain the minimum sequence derived from non-human immunoglobulins. Generally, humanized antibodies will include substantially at least one and typically all of two variable domains, all or substantially all of its hypervariable loops corresponding to those of non-human immunoglobulins, and all or substantially all of the FR regions are those of human immunoglobulin sequences. Humanized antibodies will also optionally include at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a human immunoglobulin. When it is necessary to distinguish humanized antibodies from parent rodent antibodies, prefixes "hum", "hu", "Hu" or "h" are added to the antibody clone name. The rodent antibody of humanized form will generally include the same CDR sequence of the parent rodent antibody, but some amino acid substitutions may be included to increase affinity, increase the stability of the humanized antibody, or for other reasons.

[0078] The antibodies of the present application have potential therapeutic uses in treating cancer. The term "cancer" or "tumor" herein refers to or describes a physiological condition in which a mammal is typically characterized by dysregulated cell growth. Examples of cancer include, but are not limited to, lung cancer (including small cell lung cancer or non-small cell lung cancer), adrenal cancer, liver cancer, stomach cancer, cervical cancer, melanoma, kidney cancer, breast cancer, colorectal cancer, leukemia, bladder cancer, bone cancer, brain cancer, endometrial cancer, head and neck cancer, lymphoma, ovarian cancer, skin cancer, thyroid tumor, or esophageal cancer.

[0079] In addition, the antibodies of the present application have potential therapeutic uses in controlling viral infections and other human diseases that are mechanistically related to immune tolerance or "exhaustion." In the context of the present application, the term "exhaustion" refers to a process that leads to a weakening of the ability of immune cells to respond to cancer or chronic viral infections. Anti-PD-1 antibodies

[0080] The present disclosure provides anti-PD-1 antibodies and subcutaneous formulations thereof. For example, tislelizumab (BGB-A317) is an anti-PD-1 antibody disclosed in US Pat. No. 8,735,553 having the sequence provided in Table 1 below. Table 1

[0081] Anti-PD1 antibodies may include, but are not limited to, tislelizumab, pembrolizumab or nivolumab. Tislelizumab is disclosed in US 8,735,553. Pembrolizumab (formerly known as MK-3475) disclosed by Merck in US 8,354,509 and US 8,900,587 is a humanized IgG4-K immunoglobulin that targets the PD1 receptor and inhibits the binding of PD1 receptor ligands PD-L1 and PD-L2. Pembrolizumab has been approved for indications of metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), and is being studied clinically for the treatment of head and neck squamous cell carcinoma (HNSCC) and refractory Hodgkin's lymphoma (cHL). Nivolumab (as disclosed by Bristol-Meyers Squibb) is a fully human IgG4-K monoclonal antibody. Nivolumab (clone 5C4) is disclosed in U.S. Pat. No. US 8,008,449 and WO 2006 / 121168. Nivolumab is approved for the treatment of melanoma, lung cancer, kidney cancer, and Hodgkin's lymphoma. Further changes to the Fc region framework

[0082] In other aspects, the Fc region is changed by replacing at least one amino acid residue with a different amino acid residue to change the effector function of the antibody. For example, one or more amino acids can be replaced with different amino acid residues so that the antibody has a changed affinity for the effector ligand, but retains the antigen binding ability of the parent antibody. The effector ligand with changed affinity can be, for example, an Fc receptor or the C1 component of complement. This method is described in, for example, U.S. Patent Nos. 5,624,821 and 5,648,260 by Winter et al.

[0083] In another aspect, one or more amino acid residues can be replaced with one or more different amino acid residues such that the antibody has altered CIq binding and / or reduced or abolished complement dependent cytotoxicity (CDC).This approach is described, for example, in U.S. Patent No. 6,194,551 to Idusogie et al.

[0084] On the other hand, one or more amino acid residues are changed to change the ability of the antibody to fix complement. The method is described in, for example, PCT Publication WO 94 / 29351 of Bodmer et al. In a specific aspect, one or more amino acids of the antibody or its antigen-binding fragment of the present disclosure are replaced by one or more allotype amino acid residues of IgG1 subclass and κ isotype. Allotype amino acid residues also include but are not limited to the constant region of the heavy chain of IgG1, IgG2 and IgG3 subclasses and the constant region of the light chain of κ isotype, as described in Jefferis et al., MAbs [monoclonal antibodies] 1: 332-338 (2009).

[0085] In another aspect, the Fc region is modified by modifying one or more amino acids to increase the ability of the antibody to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or to increase the affinity of the antibody for Fcγ receptors. This approach is described, for example, in PCT Publication WO 00 / 42072 by Presta. In addition, binding sites for FcγRI, FcγRII, FcγRIII, and FcRn on human IgG1 have been mapped, and variants with improved binding have been described (see Shields et al., J. Biol. Chem. [Journal of Biological Chemistry] 276: 6591-6604, 2001).

[0086] On the other hand, the glycosylation of the antibody is modified. For example, aglycosylated antibodies (i.e., antibodies lacking or having reduced glycosylation) can be prepared. For example, glycosylation can be changed to increase the affinity of the antibody to the "antigen". This carbohydrate modification can be achieved by, for example, changing one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be made, which lead to the elimination of one or more variable region framework glycosylation sites, thereby eliminating the glycosylation of the site. This glycosylation can increase the affinity of the antibody to the antigen. This method is described in, for example, U.S. Patent Nos. 5,714,350 and 6,350,861 of Co et al.

[0087] Additionally or alternatively, antibodies with altered glycosylation types can be prepared, such as hypofucosylated antibodies with reduced amounts of fucosyl residues or antibodies with increased bisecting GlcNac structures. Such altered glycosylation patterns have been shown to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished, for example, by expressing the antibody in a host cell with an altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art, and these cells can be used as host cells in which recombinant antibodies are expressed to thereby produce antibodies with altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a functionally disrupted FUT8 gene encoding a fucosyltransferase, such that antibodies expressed in such a cell line exhibit hypofucosylation. PCT Publication WO 03 / 035835 to Presta describes a variant CHO cell line, Lec13 cells, which have a reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in the host cells (see also Shields et al., (2002) J. Biol. Chem. 277:26733-26740). PCT Publication WO 99 / 54342 to Umana et al. describes a cell line engineered to express a glycoprotein-modifying glycosyltransferase (e.g., β(1,4)-N-acetylglucosamine transferase III (GnTIII)), such that antibodies expressed in the engineered cell line exhibit increased bisecting GlcNac structures, which results in increased ADCC activity of the antibodies (see also Umana et al., Nat. Biotech. 17:176-180, 1999).

[0088] On the other hand, if the desired ADCC is reduced, many previous reports show that human antibody subclass IgG4 has only moderate ADCC and almost no CDC effector function (Moore GL et al., 2010 MAbs [monoclonal antibodies], 2: 181-189). On the other hand, it was found that native IgG4 is less stable under stress conditions (such as in acidic buffers or at elevated temperatures) (Angal, S. 1993 Mol Immunol [molecular immunology], 30: 105-108; Dall'Acqua, W. et al., 1998 Biochemistry [biochemistry], 37: 9266-9273; Aalberse et al., 2002 Immunol [immunology], 105: 9-19). Reduced ADCC can be achieved by operably linking the antibody to an IgG4 engineered with a combination of alterations having reduced or ineffective FcγR binding or C1q binding activity, thereby reducing or eliminating ADCC and CDC effector functions. Considering the physicochemical properties of antibodies as biopharmaceuticals, one of the less desirable inherent properties of IgG4 is that its two heavy chains dynamically separate in solution to form half antibodies, which leads to the generation of bispecific antibodies in vivo through a process called "Fab arm exchange" (Van der Neut Kolfschoten M et al., 2007 Science, 317: 1554-157). The mutation of serine at position 228 (EU numbering system) to proline exhibits an inhibitory effect on the separation of IgG4 heavy chains (Angal, S. 1993 Mol Immunol, 30: 105-108; Aalberse et al., 2002 Immunol, 105: 9-19). It has been reported that some amino acid residues in the hinge region and the γFc region have an influence on the interaction of antibodies with Fcγ receptors (Chappel SM et al., 1991 Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America], 88:9036-9040; Mukherjee, J. et al., 1995 FASEB J [Journal of the Federation of American Societies for Experimental Biology], 9:115-119; Armour, KL et al., 1999 Eur J Immunol [European Journal of Immunology], 29:2613-2624; Clynes, RA et al., 2000 Nature Medicine [Nature Medicine], 6:443-446; Arnold JN, 2007 Annu Rev immunol [Annual Review of Immunology], 25:21-50).In addition, some rare IgG4 isotypes in the population can also cause different physicochemical properties (Brusco, A. et al., 1998 Eur J Immunogenet [European Journal of Immunogenetics], 25: 349-55; Aalberse et al., 2002 Immunol [Immunology], 105: 9-19). In order to produce PD-1 antibodies with low ADCC, CDC and instability, the hinge region and Fc region of human IgG4 can be modified and many changes can be introduced. These modified IgG4 Fc molecules can be found in SEQ ID NO: 83-88, U.S. Patent No. 8,735,553. Treatment

[0089] The antibodies or antigen-binding fragments of the present disclosure can be used in a variety of applications, including but not limited to methods of treating PD-1-related disorders or diseases. In one aspect, the PD-1-related disorder or disease is cancer.

[0090] In one aspect, the present disclosure provides a method for treating cancer. In some aspects, the method comprises administering an effective amount of an anti-PD-1 antibody or antigen binding fragment to a patient in need. Cancer may include, but is not limited to, lung cancer (including small cell lung cancer or non-small cell lung cancer), adrenal cancer, liver cancer, gastric cancer, cervical cancer, melanoma, kidney cancer, breast cancer, colorectal cancer, leukemia, bladder cancer, bone cancer, brain cancer, endometrial cancer, head and neck cancer, lymphoma, ovarian cancer, skin cancer, thyroid tumor, or esophageal cancer.

[0091] Antibodies or antigen-binding fragments of the present invention can be administered by any suitable means, including parenteral, intrapulmonary and intranasal, and if necessary for local treatment, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Administration can be by any suitable route, for example by injection, such as intravenous or subcutaneous injection, which depends in part on whether the administration is short-lived or long-term. Various dosing regimens are contemplated herein, including but not limited to single administration or multiple administrations at different time points, push injection administration and pulse infusion.

[0092] The antibody or antigen-binding fragment of the present invention can be formulated, administered and used in a manner consistent with good medical practice. Factors to be considered in this regard include the specific obstacle for treatment, the specific mammal for treatment, the clinical condition of the individual patient, the cause of the obstacle, the delivery site of the agent, the method of administration, the administration regimen and other factors known to medical practitioners. The antibody does not need to be formulated with one or more agents currently used to prevent or treat the obstacle under study. The effective amount of such other agents depends on the amount of the antibody present in the formulation, the type of obstacle or treatment and other factors discussed above. These are usually used with the same dosage and route of administration as described herein, or with about 1%-99% of the dosage described herein, or with any dosage and any route determined to be suitable by experience / clinical use.

[0093] For the prevention or treatment of disease, the appropriate dosage of the antibodies or antigen-binding fragments of the invention will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the judgment of the attending physician.

[0094] Antibodies related to PD-1 have been shown to be safe when applied to human cancer patients in various dosage ranges and administration cycles. The subcutaneous antibody formulation disclosed herein can be applied at 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, 900mg or 1000mg. Subcutaneous antibody formulations can be applied twice a day, once a day, once a week, twice a week, three times a week, four times a week, five times a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months, once every four months, once every five months or once every six months. In some embodiments, the dosing regimen includes applying tislelizumab once every three weeks at 100mg. In some embodiments, the dosing regimen includes applying tislelizumab once every three weeks at 200mg. In some embodiments, the dosing regimen includes applying tislelizumab once every three weeks at 300mg. In some embodiments, the dosing regimen includes applying tislelizumab once every three weeks at 400mg. In some embodiments, the dosing regimen comprises administering tislelizumab at 500 mg once every three weeks. In some embodiments, the dosing regimen comprises administering tislelizumab at 600 mg once every three weeks.

[0095] In certain embodiments, tislelizumab can be administered in combination with other therapies, e.g., zanubrutinib, pamiparib, anti-CTLA4 antibodies, anti-4-1BB antibodies, anti-OX40 antibodies, anti-TIGIT antibodies, anti-TIM-3 antibodies, CD40 agonists, TLR agonists, CAR-T cells, or chemotherapeutic agents. Pharmaceutical compositions and formulations

[0096] Compositions comprising pharmaceutical formulations are also provided, comprising anti-PD-1 antibodies or antigen-binding fragments thereof. In certain embodiments, the compositions comprise one or more antibodies or antigen-binding fragments that bind to PD-1. These compositions may further comprise a suitable carrier, such as a pharmaceutically acceptable excipient comprising a buffer.

[0097] Pharmaceutical formulations of the anti-PD-1 antibodies or antigen-binding fragments described herein are prepared by mixing such antibodies or antigen-binding fragments having the desired purity with one or more pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. ed. (1980)), in the form of a lyophilized formulation or an aqueous solution. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the doses and concentrations employed, and include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues); proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG) or polysorbate 20.

[0098] The present disclosure provides various pharmaceutical formulations of anti-PD1 antibodies as described in detail herein. For example, the formulation can include an anti-PD1 antibody, a buffer providing a certain pH (e.g., histidine), a sugar polyol (e.g., sucrose or trehalose), a viscosity reducer (e.g., NaCl), and a nonionic surfactant (e.g., polysorbate 20).

[0099] Sustained release preparations may be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, eg films, or microcapsules.

[0100] Formulations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes. Examples

[0101] The description of examples and certain embodiments should be considered illustrative, rather than limiting, of the present invention as defined by the claims. As will be readily appreciated, many variations and combinations of the features set forth above may be used without departing from the present invention as set forth in the claims. All such variations are intended to be included within the scope of the present invention. All references cited are incorporated herein by reference in their entirety. Analytical methods

[0102] The Methods section provides a summary of the methods used in Examples 1-5 below. SEC-HPLC

[0103] The formation of soluble aggregates was analyzed by size exclusion chromatography (SEC) on a Waters HPLC system. An isocratic gradient was used on a TSKgel G3000 maintained at 37°C ± 5°C. TM Proteins are separated by molecular size on SWXL columns. Molecular weight species are eluted and detected by UV absorption at 280 nm. The distribution of aggregates, monomers and fragments is quantified via peak areas of standards and samples. CZ

[0104] Using PA800 Plus TM (Beckman) The charge heterogeneity of the samples was determined by capillary zone electrophoresis (CZE), also known as free solution capillary electrophoresis. The samples were separated according to their electrophoretic mobilities, which are caused by differences in charge and hydrodynamic radius of the analytes in a capillary filled with a buffer solution containing hexanoic acid. When an external electric field is applied, the samples are analyzed in their native state, resulting in a specific peak pattern showing the various charge variants of the antibody (acidic, basic and primary charge variants). The samples were injected by pressure and the mobile proteins were detected by UV absorbance at 214 nm. CE-SDS(NR)

[0105] Using PA800 Plus TM(Beckman) The purity of the sample was determined by capillary gel electrophoresis (CE) method. The sample was denatured with sodium dodecyl sulfate (SDS) and separated according to size in a capillary filled with gel, which served as a sieving medium. In non-reduced (NR) samples, alkylating agent N-ethylmaleimide (NEM) was added to avoid any fragmentation induced by sample preparation, and to ensure that the main IgG peak remained intact. The sample was injected electrically, and the mobile protein was detected by the UV absorbance at 200nm using a UV detector. The reportable value of the non-reduced sample is the time-corrected area percentage (TCA)% of the IgG main peak. Protein concentration

[0106] Protein concentration was determined by UV at 280 nm. Viscosity

[0107] Viscosity of Antibody Formulations in Chip-Based MicroVISC TM The pressure difference is related to the dynamic viscosity of the solution. The sample volume is approximately 70-100 μL. An aliquot is loaded onto a 400 μL microVISC TM A disposable pipette was placed in the microarray and attached to the chip. -1 The measurements were performed in triplicate at a shear rate of 1.54°C and a temperature of approximately 25°C. Thermal stability

[0108] Using Uncle TM (Unchained Labs) determined stability by combining 3 different measurement modes - fluorescence, static light scattering (SLS) and dynamic light scattering (DLS). SLS and intrinsic fluorescence were performed to determine the onset of aggregation temperature (Tagg) and melting temperature (Tm) of the formulation, respectively. Turbidity

[0109] Using 96-well plate molecular device M2e TM The reader measures UV absorbance at 350 nm as an indication of turbidity. The absorbance readings are controlled against blank well readings and normalized to the sample path length. Visible particles

[0110] Visible particles were examined on a black background and a white background using white fluorescent light at approximately 2000 lux. The vial was gently rotated under examination and examined for no less than 5 seconds on each background. Subvisible particles Micro-Flow Imaging (MFI) TM Subvisible particles were analyzed using a ProteinSimple 5200. Water rinses were performed between each analysis. In addition, water rinses were performed before sample analysis to ensure that background counts were appropriate for the test. Average cumulative counts / mL are reported. Example 1: Effect of pH on the stability of low-concentration PD-1 antibody formulations

[0111] To determine the stability of the antibody over a pH range, tislelizumab was prepared and purified (Table 1). First, low concentrations of the antibody (10 mg / ml) were prepared by dialyzing tislelizumab into 20 mM sodium dihydrogen phosphate-citrate buffer at different pH values ​​(5.0, 5.5, 6.0, 6.5, and 7.0) using a 10 kDa MWCO dialysis cassette. The antibody solution was then filtered through a Millex 400 column. TM GP0.22μm PES 33mm filter, and filled into 2mL ready-to-use glass vials (Schott). To evaluate the effect of low concentration on antibody stability, the antibody samples were placed in a 40°C stability chamber for two weeks ( Figure 1A-B denoted as "40C2W" in the figure) and then exposed to light for two weeks in a 10°C stabilization chamber ( Figure 1A-B As a control, the samples were assayed at their initial time point (denoted as T0 in the figure). The purity of all samples was measured by SEC-HPLC and the charge heterogeneity of all samples was measured by CZE. Figure 1A-B Displayed as a graphic.

[0112] A clear trend of pH-dependent charge spectra was observed, with lower pH formulations showing higher main peaks under both thermal and light stress. The highest antibody aggregates were observed in formulations at pH 5.0, thermal stress, and at pH 7.0, light stress. In summary, SEC-HPLC results (FIG. 1A) and CZE results (FIG. 1B) show that low-concentration anti-PD-1 antibody formulations at pH 5.5-6.5 are relatively more stable than those at pH 5.0 and 7.0. Therefore, it can be concluded that the pH range of pH 5.5-6.5 provides stability for antibodies. Example 2: Effect of pH on Viscosity and Stability of High Concentration PD-1 Antibody Formulations

[0113] Where the pH range was determined at low antibody concentrations, this data was used for experiments with high antibody concentrations. To prepare tislelizumab stock solutions, tislelizumab was buffer exchanged into the different buffers listed in Table 2 using a 10 kDa MWCO dialysis cassette. To prepare high concentration formulations containing trehalose (150 mM), the high concentration trehalose stock solution was spiked into the tislelizumab stock solution and then dialysis was performed using a 30 kDa Amicon Ultra TM The centrifugal filter was concentrated to approximately 150 mg / ml of tislelizumab.

[0114] Protein concentration and viscosity were measured. The results are shown in Table 2. The results show that the formulations prepared in histidine-histidine HCl buffers at pH 5.5 and pH 6.0 exhibited the lowest viscosity. Tislelizumab at a concentration of 150 mg / ml in the same histidine-histidine HCl buffer, but resulted in higher viscosity when the pH was higher than 6.0. As shown in Table 2, Tislelizumab formulations F4 and F5 provided good results in terms of good viscosity and low aggregation. It is noteworthy that the viscosity (cP) of Tislelizumab antibody formulation F5 is 15.53, and the aggregation is 2.99.

[0115] To determine the freeze-thaw stability of high concentration (approximately 150 mg / mL) tislelizumab formulations, each formulated tislelizumab solution was passed through a Millex TM GP 0.22 μm PES 33mm filter is filtered and filled into 2mL glass vials. The sample is subjected to three cycles (freeze-thaw (3FT)) of freezing at -40 ° C and thawing at room temperature. In addition, the sample is stored at 40 ° C for 2 weeks (40C2W). Aggregation formation is evaluated by SEC-HPLC. As a control, the sample is analyzed at its initial time point, which is represented as T0 in the table. The results are summarized in Table 2. The SEC-HPLC results show that similar amounts of aggregates are formed in the formulation spectrum tested in the freeze-thaw experiment, and most of the values ​​between the initial time point and the end of freeze-thaw are the same. This shows that these tislelizumab antibody formulations provide appropriate stability for antibodies at high concentrations. Regarding the tislelizumab antibody formulations stored at 40 ° C for 2 weeks (40C2W), it was detected that the aggregates increased by about 0.6% to 1.5%, which again shows that these formulations provide appropriate stability for tislelizumab antibodies at high concentrations. The lowest amount of aggregates was observed for Formulation 4 (F4) stored at 40°C for 2 weeks and Formulation 5 (F5) through freeze-thaw cycles.

[0116] Considering both aggregation and solution viscosity, high concentration anti-PD-1 antibody formulations comprising histidine-histidine HCl buffer (particularly pH 6.0) produced the best results. Table 2. Viscosity and aggregate formation of high concentration PD-1 antibody formulations in different buffers Note: T0 refers to the initial time point of the sample. 40C2W refers to the sample after two weeks of storage at 40°C. Freeze-thaw (3FT) refers to the sample undergoing three freeze and thaw cycles. Example 3: Evaluation of the conformational and colloidal stability of low concentration PD-1 antibody formulations containing NaCl

[0117] This experiment determines the effect of pH and NaCl on the conformation and colloidal stability of anti-PD-1 antibodies. In this study, NaCl and trehalose stock solutions of different concentrations in 20mM histidine-histidine HCl buffer at pH 5.5, 6.0 and 6.5 were prepared. Subsequently, tislelizumab was exchanged into 20mM histidine-histidine HCl buffer (pH 5.5, 6.0 and 6.5) by dialysis buffer to prepare tislelizumab stock solution. Trehalose stock solution and / or NaCl stock solution were incorporated into tislelizumab stock solution to obtain the desired target excipient concentration (Table 3). The final antibody concentration of each sample was adjusted to 10mg / ml.

[0118] The conformational and colloidal stability of tislelizumab in formulations containing NaCl were evaluated by measuring the midpoint unfolding temperature (Tm) and the onset aggregation temperature (Tagg) (Table 3). As the NaCl concentration increased, the Tm and Tagg values ​​showed a clear downward trend, while as the pH increased, the Tm and Tagg values ​​showed a slight upward trend. Adding 150mM NaCl significantly reduced the conformational and colloidal stability of the tislelizumab formulation. These results indicate that at low antibody concentrations, the tislelizumab formulations of pH 5.5-6.0 and 50-100mM NaCl exhibited the best conformational and colloidal stability. Table 3. Midpoint unfolding temperature and aggregation temperature of low concentration anti-PD-1 antibody formulations Example 4: Viscosity of High Concentration PD-1 Antibody Formulations

[0119] This experiment determined the effect of different concentrations of trehalose and NaCl on the viscosity of high concentration anti-PD-1 antibody formulations. In this study, different concentrations of NaCl and trehalose stock solutions in 20mM histidine-histidine HCl buffer at pH 6.0 were prepared. Subsequently, tislelizumab was exchanged into 20mM histidine-histidine HCl buffer (pH 6.0) by dialysis buffer to prepare a high concentration tislelizumab stock solution. Trehalose stock solution and / or NaCl stock solution were incorporated into tislelizumab high concentration antibody stock solution (Table 4 and Table 5). By using 30kDa AmiconUltra TM Centrifugal filters concentrate samples to different concentrations.

[0120] Viscosity analysis at 500S -1 The results are shown in Table 4. The data show that the viscosity of the anti-PD-1 antibody formulation increases exponentially with increasing antibody concentration. Compared with the alkaline buffer formulation, the addition of 100mM trehalose and 240mM trehalose increased the viscosity, whether it was 100mM trehalose or especially the higher concentration of 240mM trehalose. Subcutaneous formulations have the element of "syringe ability", that is, the ability of subcutaneous formulations to be administered through a syringe (e.g., 20-25 gauge) needle. Therefore, it is necessary to add a viscosity reducer.

[0121] It is noteworthy that the addition of 50mM NaCl reduced the viscosity of the high concentration anti-PD-1 antibody formulation. In contrast, the addition of 100mM NaCl produced the same viscosity reduction, while 140mM NaCl caused a slightly more prominent viscosity reduction effect. As shown in Example 3, the tislelizumab antibody formulated at pH 5.5-6.0 and 50-100mM NaCl showed the best conformational and colloidal stability. Considering the viscosity reduction as well as the conformational and colloidal stability, the addition of 50-100mM NaCl was considered in the high concentration anti-PD-1 antibody formulation. Table 4. Effects of NaCl and trehalose on solution viscosity of high concentration anti-PD-1 antibody formulations (pH 6.0) containing 20 mM histidine

[0122] The viscosity and osmotic pressure of anti-PD-1 antibody formulations containing 50-100 mM NaCl in the presence of trehalose were also studied (shown in Table 5). The results showed that the viscosity values ​​of the combination of 50 mM NaCl and 100 mM trehalose at 154.70 mg / ml of tislelizumab were similar, with a viscosity of 13.98 cP. The viscosity of the combination of 70 mM NaCl and 80 mM trehalose at 152 mg / ml of tislelizumab was 13.43 cP, while the viscosity of 100 mM NaCl and 70 mM trehalose at 153.64 mg / ml of tislelizumab was 11.52 cP.

[0123] When the antibody concentration reaches about 180mg / ml, the viscosity value is about 30cP. In terms of viscosity, all the formulations tested show improved syringe capacity. In particular, the viscosity produced by the high-concentration tislelizumab formulation shows good compatibility with syringes containing 23 or 25 needles commonly used for subcutaneous administration. In addition, the viscosity of the combination of 50mM NaCl and 100mM trehalose (33.19cP at 184.51mg / ml antibody concentration) is higher than the viscosity of 50mM NaCl alone (26.92cP at 182.49mg / mL), which shows that considering adding no more than 100mM trehalose is based on considerations of viscosity and osmotic pressure. Table 5. Effect of NaCl and trehalose combination on solution viscosity and osmotic pressure of high concentration anti-PD-1 antibody formulations (pH 6.0) containing 20 mM histidine Example 5: Stability of high concentration PD-1 antibody formulation

[0124] The stability of high concentration tislelizumab antibodies was evaluated in various formulations listed in Table 6. All formulations were prepared in 20 mM histidine-histidine HCl buffer at pH 6.0. Formulations F15 and F16 were prepared in a combination of 100 mM NaCl and 70 mM trehalose, while formulation F17 was prepared in a combination of 50 mM NaCl and 100 mM trehalose. - In these formulations, the concentration of polysorbate 20 ranged from 0 to 0.8 mg / mL (equivalent to 0.08%).

[0125] Tislelizumab was buffer exchanged into 20 mM histidine-histidine HCl buffer (pH 6.0) by dialysis to produce a tislelizumab stock solution. A stock solution of NaCl and trehalose combined in 20 mM histidine-histidine HCl buffer at pH 6.0 was prepared and spiked into the tislelizumab stock solution. Subsequently, a 30 kDa Amicon Ultra TMThe centrifugal filter concentrated the sample to approximately 150 mg / mL. Formulations with different concentrations of polysorbate 20 (PS20: 0, 0.2 mg / ml, and 0.8 mg / ml) were prepared by adding high concentration PS20 stock solutions. Each formulation solution was filtered using a 0.22 μm PES syringe filter and filled into 2 mL ready-to-use glass vials with a filling volume of 0.5 mL of drug product.

[0126] Freeze-thaw studies were performed by subjecting the vials to three cycles of freezing at -40 ° C and thawing at ambient temperature (denoted as "3FT" in the figure). In order to study the high temperature stability and stirring stability of the formulations, the samples were stored in a 40 ° C stabilization chamber for 4 weeks (denoted as "40C4W" in the figure), or mechanically stressed by stirring for 48 hours (denoted as "SK" in the figure). The formulations were evaluated by A350, SEC (purity), CZE (charge spectrum) and CE-SDS (NR) (purity). As a control, the samples were analyzed at their initial time point (denoted as T0 in the figure). These results are provided in Table 8 and Figures 2-4.

[0127] The turbidity of the drug product was determined by measuring the optical density at 350 nm. The samples stored at 40°C and 25°C showed a slight increase in turbidity, while the A350 of the PS20-free sample was found to be higher than the other samples. Under shaking conditions, a more pronounced increase in A350 was observed in the PS20-free sample, while no significant changes were observed in the other samples. There was no measurable change in turbidity after freeze-thaw stress for any formulation.

[0128] At 40°C, a slight decrease in antibody stability was observed in formulations F15, F16 and F17, and the amount of aggregates increased accordingly. In addition, after oscillation and freeze-thaw stress, the SEC purity of the formulations did not change significantly. The SEC purity of all formulations was within the clinical acceptance criteria of 95.0% of the monomer. Samples stored at 40°C showed a decrease in the main peak % and the total alkaline peak % (data not shown), with a corresponding increase in the acidic peak % (data not shown). CE-SDS (NR) purity showed that storage at 40°C for 4 weeks only resulted in a slight decrease in monomers. At 40°C, there was no difference between different formulations.

[0129] In summary, these results indicate that high concentration tislelizumab formulations (e.g., F16 and F17) containing PS20 are stable after 6 months of storage at 5°C and 25°C under stirring, freeze-thaw and heat stress. Subsequently, additional studies were conducted to determine the long-term stability and accelerated stability of formulation 18 (F18), which contains 70mM NaCl and 80mM trehalose. Concentrated tislelizumab drug substance was prepared at approximately 200mg / mL by concentration and diafiltration in 20mM histidine-histidine HCl buffer (pH 6.0). Formulation F18 was prepared by incorporating stock solutions of NaCl, trehalose and polysorbate 20 into tislelizumab drug substance to obtain the target composition listed in Table 6. Each formulation solution was filtered using a 0.22μm PES syringe filter and filled into a 2mL ready-to-use glass vial with a fill volume of 2mL drug product. Samples were staged and placed in stability chambers at 5°C ± 3°C and 25°C with 2 vials per time point. The planned duration of the study was 24 months at 5°C ± 3°C and 6 months at 25°C.

[0130] Table 9 summarizes the visible and subvisible particle results for Formulation F18 at 152 mg / ml for up to 24 months. SEC (purity), CZE (charge spectrum), and CE-SDS (NR) (purity) results for up to 24 months Figure 5A-D Presented in. Formulation F18 at 152 mg / ml was visually inspected and found to be essentially free of visible particles at 5°C±3°C for 24 months and at 25°C for 6 months. No significant changes in subvisible particles were observed at 5°C±3°C, and an increase in particles ≥10 μm was detected at 25°C. In addition, no significant changes in aggregates, SEC monomers, CZE main peak, and CE-SDS (NR) purity were observed at 5°C±3°C. Storage at 25°C for 6 months resulted in a slight increase in aggregates and a decrease in the purity of the sample main peaks CZE and CE-SDS (NR). However, for liquid formulations with an expected storage condition of 5°C±3°C, the increase in subvisible particles and aggregates at 25°C and the decrease in the main peaks of CZE and CE-SDS (NR) purity are acceptable.

[0131] Therefore, considering all these results, formulations F16, F17 and F18 are suitable subcutaneous anti-PD1 antibody formulations for clinical use. In particular, based on several months of stability data, formulation F18 at 152 mg / ml was stable for up to 24 months under the recommended storage condition of 5°C with no measurable changes in its product quality attributes. Table 6. Composition of formulations used in stability studies Table 7. Stability study plan for formulations Table 8. Turbidity results for formulations F15, F16 and F17 Note: 40C4W means the sample was stored at 40°C for 4 weeks. 3FT means the sample was subjected to 3 freeze-thaw cycles. 25C6M means the sample was stored at 25°C for 6 months. 5C6M means the sample was stored at 5°C for 6 months. Table 9. Stability data of formulation F18 at 5°C and 25°C Note: VPF means no visible particles. 5C means samples are stored at 5℃±3℃. 25C means samples are stored at 25℃. Example 6: Bioavailability of Subcutaneous Injection

[0132] To test the bioavailability of the subcutaneous formulation, Formulation 18 (F18, Table 6) was used. Tislelizumab was administered intravenously (iv) to mice and compared with 10 mpk (mg / kg) F18 subcutaneously administered to the back of the animal, 10 mpk subcutaneously administered to the abdomen of the animal, or 20 mpk subcutaneously administered to the abdomen of the animal. For this study, C57 mice with knock-in human PD1 were used. The overall bioavailability of subcutaneous injection was 75.8%. The data are shown in Table 10 below. Table 10. Subcutaneous administration of tislelizumab to C57-hPD1 mice Note: sc-B, subcutaneous injection in back; sc-A, subcutaneous injection in abdomen

[0133] In different studies, NOD-SCID mice were used. Tislelizumab was administered intravenously (iv) to mice and compared with 10 mpk (mg / kg) F18 subcutaneously administered to the back of the animal, 20 mpk subcutaneously administered to the back of the animal, 10 mpk subcutaneously administered to the abdomen of the animal, or 20 mpk subcutaneously administered to the abdomen of the animal. The overall bioavailability of subcutaneous injection was 54.8%. The data are shown in Table 11 below. Table 11. Subcutaneous administration of tislelizumab to NOD-SCID mice Note: sc-B, subcutaneous injection in back; sc-A, subcutaneous injection in abdomen

[0134] The F18 formulation was also tested in a larger animal, the Sprague Dawley rat. Tislelizumab was administered intravenously at 100 mpk (10 mg / ml), subcutaneously to the abdomen of rats at 100 mpk (150 mg / ml), subcutaneously to the abdomen at 100 mpk (100 mg / ml), subcutaneously to the abdomen at 200 mpk (150 mg / ml), or subcutaneously to the back at 100 mpk (150 mg / ml). The overall bioavailability was 57.2%, and this data is shown in Table 1. Fig. 6A -B.

[0135] The F18 tislelizumab formulation was also tested in a minipig model. For this study, 6 mpk was administered intravenously to minipigs, while 6 mpk was injected subcutaneously into the leg or 6 mpk was injected subcutaneously behind the animal's ear. The overall bioavailability of tislelizumab by subcutaneous injection was 79.8%. The data is shown in Table 12 below. Table 12. Subcutaneous administration of tislelizumab to miniature pigs

[0136] Finally, a subcutaneous formulation of tislelizumab was tested in a monkey PK study. Three monkeys were given 30 mg / kg of the F18 tislelizumab formulation, with blood collected at 0, 4 hours, 8 hours, 24 hours, 48 ​​hours, 4 days, 7 days, 14 days, and 21 days after dosing. The results are shown in Figure 7 In the study, the subcutaneous results were compared to the AUC from a previous monkey study using the IV formulation and administration. There were no significant changes in body weight and no clinical pathology was found. No histopathological changes were found at the injection site.

[0137] The subcutaneous formulation of tislelizumab was well tolerated, with no injection site reactions in rats or minipig models, regardless of injection site or concentration used. Figure 8 as shown in .

Claims

1. A low viscosity pharmaceutical formulation comprising: about 10 mg / mL to about 200 mg / mL of an anti-programmed death receptor 1 (PD-1) antibody, or an antigen-binding fragment thereof; a formulation buffer providing a pH of about 5.0 to about 7.0; Sugar polyols; Viscosity reducers; and Nonionic surfactants, The viscosity of the pharmaceutical formulation does not exceed 30 cP, and the osmolarity is from about 200 mOsmol / kg to about 400 mOsmol / kg.

2. The formulation of claim 1, wherein the PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (a) HCDR1 (heavy chain complementary determining region 1) of SEQ ID NO: 1, (b) HCDR2 of SEQ ID NO: 2, (c) HCDR3 of SEQ ID NO: 3, and the light chain variable region comprising: (d) LCDR1 (light chain complementary determining region 1) of SEQ ID NO: 4, (e) LCDR2 of SEQ ID NO: 5, and (f) LCDR3 of SEQ ID NO:

6.

3. The formulation of claim 2, wherein the formulation buffer is selected from the group consisting of histidine, acetate, citrate, succinate, phosphate, a mixture of histidine and acetic acid, or a mixture of histidine and citric acid.

4. The formulation of claim 3, wherein the formulation buffer is histidine.

5. The formulation of claim 4, wherein the concentration of the buffer is 15 mM to 25 mM.

6. The formulation of claim 5, wherein the formulation comprises 20 mM histidine buffer.

7. The formulation of claim 5 or 6, wherein the pH is 5.5-6.

0.

8. The formulation of any one of claims 1 to 7, wherein the sugar polyol is selected from the group consisting of trehalose, sucrose, sorbitol, mannitol, maltose, dextran, or (2-hydroxypropyl)-β-cyclodextrin.

9. The formulation of claim 8, wherein the sugar polyol is trehalose.

10. The formulation of any one of claims 1 to 9, wherein the trehalose concentration is 70 mM to 240 mM.

11. The formulation of claim 10, wherein the trehalose concentration is 80 mM to 160 mM.

12. The formulation of claim 10, wherein the trehalose concentration is 70 mM to 100 mM.

13. The formulation of claim 12, wherein the trehalose concentration is 80 mM.

14. The formulation of any one of claims 1-13, wherein the viscosity reducing agent is an inorganic salt selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium sulfate, ammonium chloride or ammonium sulfate.

15. The formulation of claim 14, wherein the inorganic salt is sodium chloride at a concentration of 50 mM to 150 mM.

16. The formulation of claim 15, wherein the concentration of the sodium chloride is 50 mM to 100 mM.

17. The formulation of claim 16, wherein the sodium chloride concentration is 70 mM.

18. The formulation of any one of claims 1-17, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, or poloxamer 188.

19. The formulation of claim 18, wherein the concentration of polysorbate 20 is 0.02% to 0.08%.

20. The formulation of claim 19, wherein the polysorbate 20 concentration is 0.08%.

21. The formulation of claim 1, wherein the formulation comprises 20 mM histidine-histidine HCl, 100 mM NaCl, 70 mM trehalose and 0.08% polysorbate 20, and its pH is pH 6.

0.

22. The formulation of claim 1, wherein the formulation comprises 20 mM histidine-histidine HCl, 50 mM NaCl, 100 mM trehalose and 0.02% polysorbate 20 at a pH of pH 6.

0.

23. The formulation of claim 1, wherein the formulation comprises 20 mM histidine-histidine HCl, 70 mM NaCl, 80 mM trehalose and 0.08% polysorbate 20 at a pH of pH 6.

0.

24. The formulation of any one of claims 1 to 23, wherein the concentration of the anti-human PD-1 antibody, or antigen-binding fragment thereof, is about 100 mg / mL to 200 mg / mL.

25. A method for preparing an antibody formulation, the method comprising: a. adding trehalose and sodium chloride to the antibody to obtain an antibody formulation in which the concentration of trehalose is not less than 50 mM and the concentration of sodium chloride is not less than 25 mM, wherein the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (a) HCDR1 (heavy chain complementary determining region 1) of SEQ ID NO: 1, (b) HCDR2 of SEQ ID NO: 2, (c) HCDR3 of SEQ ID NO: 3, and the light chain variable region comprising: (d) LCDR1 (light chain complementary determining region 1) of SEQ ID NO: 4, (e) LCDR2 of SEQ ID NO: 5, and (f) LCDR3 of SEQ ID NO: 6; b. concentrating the antibody preparation of (a) to 150-200 mg / mL; and c. adding polysorbate 20 to the antibody formulation of (b) to obtain an antibody formulation having a polysorbate 20 concentration of not less than 0.01 mg / mL, wherein the antibody formulation of (c) is in aqueous solution and has a viscosity of no more than 30 cP at 25°C, and wherein the antibody formulation of (c) is stable after agitation, freeze-thaw and thermal stress.

26. A method for treating cancer in a human patient in need thereof, the method comprising subcutaneously administering an effective amount of the anti-human PD-1 antibody formulation of claim 1.

27. The method of claim 26, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of about 100 mg to about 1000 mg.

28. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 200 mg.

29. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 300 mg.

30. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 400 mg.

31. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously at a dose of 500 mg.

32. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once a week.

33. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once every 2 weeks.

34. The method of claim 27, wherein the anti-human PD-1 antibody formulation is administered subcutaneously once every 3 weeks.

35. The method of claim 26, wherein the cancer is lung cancer (including small cell lung cancer, or non-small cell lung cancer), adrenal cancer, liver cancer, stomach cancer, cervical cancer, melanoma, kidney cancer, breast cancer, colorectal cancer, leukemia, bladder cancer, bone cancer, brain cancer, endometrial cancer, head and neck cancer, lymphoma, ovarian cancer, skin cancer, thyroid tumor, or esophageal cancer.

36. The method of claim 26, wherein at least one other therapeutic agent is administered to the human patient.

37. The method of claim 36, wherein the at least one other therapeutic agent is zanubrutinib, pamiparib, an anti-CTLA4 antibody, an anti-4-1BB antibody, an anti-OX40 antibody, an anti-TIGIT antibody, an anti-TIM-3 antibody, a second PD-1 antibody, a CD40 agonist, a TLR agonist, a CAR-T cell, or a chemotherapeutic agent.

Citation Information

Cited By

  • Anti-PD-1 antibody pharmaceutical composition

    WO2026208998A1